Baird notes that the FDA announced a final rule detailing its planned future regulation of laboratory developed tests, or “LDTs,” stating that while the firm is still reading through the full rule, initial thoughts include that the final rule has several changes compared to September’s proposed version that the firm views as positive for its Life Sciences and Diagnostics coverage. The firm, which views this update as favorable for its coverage given the enforcement discretion policies around currently marketed LDTs and LDTs approved by NYS CLEP, lists Castle Biosciences (CSTL), Exact Sciences (EXAS), Illumina (ILMN), Natera (NTRA) and Bio-Techne (TECH) as among its Life Sciences and Diagnostics coverage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Secures Loan and Reshuffles Board
- Castle Biosciences management to meet virtually with Stephens
- Castle’s DecisionDx-SCC study shows predictive accurracy with patients
- Castle Biosciences management to meet with KeyBanc
- Castle Biosciences price target raised to $37 from $33 at Scotiabank
